Home - MGC Pharma CBD Health

MXC: $0.08

Who

MGC Pharmaceuticals Limited (‘MGC’) (ASX: MXC) is a biopharma company with a “Nature to Medicine” strategy at the forefront of the emerging phytocannabinoid and plant derived medicine markets. The company’s mission is to build an innovative, global bio-pharma company providing standardised, affordable plant derived medicines of the highest regulatory compliance for targeted global markets.

What

MGC currently holds pipelines for phytocannabinoid-based medications and unique formulations (Phytomedicines), both proprietary and for third parties, all under GMP certified regulations and facilities. This includes our ability to create API (Active Pharmaceutical Ingredient) of various phytocannabinoids alongside compounding to be used in the pharmaceutical treatment and research globally. MGC has developed an efficient production pipeline of phytocannabinoid derived medications, with multiple products currently being prescribed to patients, and products in clinical development and testing.

Why

We’re devoted to providing value to shareholders and providing you with the latest company information. This comprises of ASX announcements, financial reports, and other significant updates. You can also access FAQs and see the latest share price information here. MGC Pharmaceuticals trades on the Australian Securities Exchange (ASX) under the ASX code MXC.

Latest ASX Announcements

3/3/21SwissPharmaCan AG increases initial purchase order 26/2/21Half Yearly Report and Accounts 25/2/21Notice of Meeting and Incentive Share Plan 18/2/21Master Suppy and Distribution Agreement for ArtemiC Rescue

Research Reports

18/2/20The Green Fund Research Report 9/10/19Alacrita Market Projections Report 11/7/19Edison Report 24/5/19Research Publication on the Effectiveness of Cannabinoids on Glioblastoma

Distributors

Education and Patient Access Partners

Research and Academia